X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.260
-0.040 (-1.21%)
At close: Sep 12, 2025, 4:00 PM EDT
3.210
-0.050 (-1.53%)
After-hours: Sep 12, 2025, 7:53 PM EDT
X4 Pharmaceuticals Stock Forecast
XFOR's stock price has decreased by -84.2% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover X4 Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $34.17, which forecasts a 948.16% increase in the stock price over the next year. The lowest target is $3.50 and the highest is $90.
Price Target: $34.17 (+948.16%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $30 → $9 | Strong Buy | Maintains | $30 → $9 | +176.07% | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $3.5 | Strong Buy | Maintains | $7 → $3.5 | +7.36% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.5 → $7 | Strong Buy | Maintains | $1.5 → $7 | +114.72% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,280.37% | Mar 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $90 | Buy | Reiterates | $90 | +2,660.74% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
36.15M
from 2.56M
Increased by 1,313.84%
Revenue Next Year
21.82M
from 36.15M
Decreased by -39.63%
EPS This Year
-4.90
from -5.59
EPS Next Year
-2.95
from -4.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.5M | 35.9M | |||
| Avg | 36.2M | 21.8M | |||
| Low | 33.8M | 11.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,407.0% | -0.7% | |||
| Avg | 1,313.8% | -39.6% | |||
| Low | 1,221.6% | -69.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -1.19 | |||
| Avg | -4.90 | -2.95 | |||
| Low | -7.75 | -4.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.